CIK 0000949858
- Non-accelerated filer
- Smaller reporting company
ACHIEVE LIFE SCIENCES, INC.
Sign in to watch- Tickers
- ACHV QUIT
- Exchange
- Nasdaq
- Industry
- In Vitro & In Vivo Diagnostic Substances
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 954343413
- Phone
- +1 425-686-1500
- Business address
- 22722 29TH DR. SE, SUITE 100, SEATTLE, WA, 98021
- Former names
- ONCOGENEX PHARMACEUTICALS, INC., SONUS PHARMACEUTICALS INC
Securities
- ACHV Common stock Nasdaq
- QUIT Common Shares Nasdaq
- 4 Exercise or conversion EVP, CMO acquired 10,000 shares (option exercise)
- 4 Exercise or conversion President and CEO acquired 5,000 shares (option exercise)
- 4 Exercise or conversion Director acquired 3,347 shares (option exercise)
- 4 Exercise or conversion Principal Accounting Officer acquired 1,875 shares (option exercise)
- 4 Open-market sale President and CEO sold 10,000 shares at $16.52 ($165,200)
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Exercise or conversion President and CEO acquired 5,000 shares (option exercise)
- 4 Open-market sale President and CEO sold 5,000 shares at $16.02 ($80,100)
- 4 Open-market sale President and CEO sold 5,000 shares at $15.99 ($79,950)
- 4 Open-market buy Principal Financial Officer bought 650 shares at $15.73 ($10,225)
- 4 Open-market sale President and CEO sold 5,000 shares at $15.45 ($77,250)
- 4 Exercise or conversion President & CEO acquired 1,761 shares (option exercise)
- 4 Derivatives Options or other derivatives
- 3 Insider Initial Statement of Ownership
- 4 Open-market sale Former Director sold 2,557 shares at $13.02 ($33,292)
- 4 Open-market sale Director sold 1,943 shares
- 4 Open-market sale Director sold 4,833 shares
Page 17 of 24 · 465 filings